Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Development and Usability Analysis of a Multimedia eConsent Solution.

Schneiderheinze H, Prokosch HU, Apel H, Bellut L, Wullich B, Trollmann R, Schüttler C.

Stud Health Technol Inform. 2019 Sep 3;267:297-303. doi: 10.3233/SHTI190841. Review.

PMID:
31483285
2.

[Treatment of benign prostatic hyperplasia in geriatric patients-use and limitations of existing guidelines].

Schoeb DS, Wullich B, Dürschmied D, Heimbach B, Heupel-Reuter M, Gross AJ, Wilhelm K, Gratzke C, Miernik A.

Urologe A. 2019 Sep;58(9):1029-1038. doi: 10.1007/s00120-019-0988-0. Review. German.

PMID:
31451881
3.

Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma (NVUC).

Weyerer V, Weisser R, Moskalev EA, Haller F, Stoehr R, Eckstein M, Zinnall U, Gaisa NT, Compérat E, Perren A, Keck B, Allory Y, Kristiansen G, Wullich B, Agaimy A, Hartmann A, Bertz S.

Histopathology. 2019 Jul 26. doi: 10.1111/his.13958. [Epub ahead of print]

PMID:
31348552
4.

68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.

Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, Uder M, Wullich B, Goebell P, Bäuerle T.

Ann Nucl Med. 2019 Jul 23. doi: 10.1007/s12149-019-01387-0. [Epub ahead of print]

PMID:
31338731
5.

Megaprepuce: presentation of a modified surgical technique with excellent cosmetic and functional results.

Hirsch K, Schwaiger B, Kraske S, Wullich B.

J Pediatr Urol. 2019 Aug;15(4):401.e1-401.e6. doi: 10.1016/j.jpurol.2019.05.018. Epub 2019 May 25.

PMID:
31301977
6.

Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2).

Merten R, Ott O, Haderlein M, Bertz S, Hartmann A, Wullich B, Keck B, Kühn R, Rödel CM, Weiss C, Gall C, Uter W, Fietkau R.

Oncologist. 2019 Jul 10. pii: theoncologist.2018-0280. doi: 10.1634/theoncologist.2018-0280. [Epub ahead of print]

PMID:
31292267
7.

Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistofluorescence on prostate cancer tissue microarrays.

Eckstein M, Sailer V, Nielsen BS, Wittenberg T, Wiesmann V, Lieb V, Nolte E, Hartmann A, Kristiansen G, Wernert N, Wullich B, Taubert H, Wach S; German Prostate Cancer Consortium (DPKK).

Lab Invest. 2019 Jun 11. doi: 10.1038/s41374-019-0251-8. [Epub ahead of print]

PMID:
31186527
8.

Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma.

Kahlmeyer A, Stöhr CG, Hartmann A, Goebell PJ, Wullich B, Wach S, Taubert H, Erlmeier F.

J Clin Med. 2019 May 24;8(5). pii: E743. doi: 10.3390/jcm8050743.

9.

[The 16th DPKK annual conference "Urology meets Pathology"].

Taubert H, Becker C, Füssel S, Seitz G, Kristiansen G, Wach S, Wullich B.

Urologe A. 2019 Jun;58(6):686-689. doi: 10.1007/s00120-019-0941-2. German. No abstract available.

PMID:
31069452
10.

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany.

Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

PMID:
30988029
11.

[Geriatric urology].

Wullich B, Wiedemann A.

Urologe A. 2019 Apr;58(4):369. doi: 10.1007/s00120-019-0912-7. German. No abstract available.

PMID:
30953101
12.

Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo.

Wach S, Brandl M, Borchardt H, Weigelt K, Lukat S, Nolte E, Al-Janabi O, Hart M, Grässer F, Giedl J, Jung R, Stöhr R, Hartmann A, Lieb V, Höbel S, Peters A, Stäubert C, Wullich B, Taubert H, Aigner A.

Mol Ther Nucleic Acids. 2019 Jun 7;16:272-283. doi: 10.1016/j.omtn.2019.02.020. Epub 2019 Feb 27.

13.

[Presurgical assessments].

Kahlmeyer A, Goebell PJ, Wullich B.

Urologe A. 2019 Apr;58(4):373-380. doi: 10.1007/s00120-019-0888-3. Review. German.

PMID:
30830292
14.

Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.

Kunath F, Goebell PJ, Wullich B, Sikic D, Kahlmeyer A.

World J Urol. 2019 Mar 4. doi: 10.1007/s00345-019-02704-y. [Epub ahead of print]

PMID:
30830274
15.

Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients.

Stöhr CG, Steffens S, Polifka I, Jung R, Kahlmeyer A, Ivanyi P, Weber F, Hartmann A, Wullich B, Wach S, Taubert H.

Sci Rep. 2019 Feb 11;9(1):1741. doi: 10.1038/s41598-018-38254-3.

16.

[Urology vision 2025].

Klotz T, Zumbé J, Wullich B.

Urologe A. 2019 Jan;58(1):53. doi: 10.1007/s00120-018-0844-7. German. No abstract available.

PMID:
30666376
17.

No Evidence of Microsatellite Instability and Loss of Mismatch-Repair-Protein Expression in Squamous Cell Carcinoma of the Penis.

Stoehr R, Wendler O, Giedl J, Gaisa NT, Richter G, Campean V, Burger M, Wullich B, Bertz S, Hartmann A.

Pathobiology. 2019;86(2-3):145-151. doi: 10.1159/000495251. Epub 2019 Jan 16.

PMID:
30650417
18.

Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review.

Pinart M, Kunath F, Lieb V, Tsaur I, Wullich B, Schmidt S; German Prostate Cancer Consortium (DPKK).

World J Urol. 2018 Dec 15. doi: 10.1007/s00345-018-2574-2. [Epub ahead of print]

PMID:
30554274
19.

Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients.

Eckstein M, Jung R, Weigelt K, Sikic D, Stöhr R, Geppert C, Agaimy A, Lieb V, Hartmann A, Wullich B, Wach S, Taubert H.

Sci Rep. 2018 Dec 6;8(1):17693. doi: 10.1038/s41598-018-35637-4.

20.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F.

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

PMID:
30528808
21.

P53 Codon 72 Polymorphism and Risk for Squamous Cell Carcinoma of the Penis: A Caucasian Case-Control Study.

Stoehr R, Weisser R, Wendler O, Giedl J, Daifalla K, Gaisa NT, Richter G, Campean V, Burger M, Wullich B, Hartmann A.

J Cancer. 2018 Oct 20;9(22):4234-4241. doi: 10.7150/jca.26050. eCollection 2018.

22.

[UroEvidence opens new call for applications].

Schmidt S, Kunath F, Wullich B.

Urologe A. 2018 Dec;57(12):1488-1489. doi: 10.1007/s00120-018-0812-2. Review. German. No abstract available.

PMID:
30413864
23.

Expression of GP88 (progranulin) in serum of prostate cancer patients is associated with Gleason scores and overall survival.

Greither T, Fischer K, Theil G, Marcou M, Holzhausen HJ, Weigelt K, Serrero G, Hicks D, Yue B, Fornara P, Wullich B, Taubert H, Wach S, Lieb V.

Cancer Manag Res. 2018 Oct 5;10:4173-4180. doi: 10.2147/CMAR.S172069. eCollection 2018.

24.

[Urological challenges in refugees and migrants].

Wullich B, Alloussi S.

Urologe A. 2018 Oct;57(10):1183-1184. doi: 10.1007/s00120-018-0765-5. German. No abstract available.

PMID:
30288573
25.

Effects of whole-body electromyostimulation combined with individualized nutritional support on body composition in patients with advanced cancer: a controlled pilot trial.

Schink K, Herrmann HJ, Schwappacher R, Meyer J, Orlemann T, Waldmann E, Wullich B, Kahlmeyer A, Fietkau R, Lubgan D, Beckmann MW, Hack C, Kemmler W, Siebler J, Neurath MF, Zopf Y.

BMC Cancer. 2018 Sep 12;18(1):886. doi: 10.1186/s12885-018-4790-y.

26.

[Renal transplantation: Opportunities and risks for medical refugees].

Mammadova D, Hirsch K, Schwaiger B, Wullich B, Rascher W.

Urologe A. 2018 Oct;57(10):1200-1207. doi: 10.1007/s00120-018-0759-3. German.

PMID:
30132015
27.

High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma.

Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stöckle M, Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler M, Stief C, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Höfler H, Haferkamp A, Geppert CI, Stöhr C, Hartmann A; German Network Of Kidney Cancer.

Hum Pathol. 2019 Jan;83:212-223. doi: 10.1016/j.humpath.2018.08.006. Epub 2018 Aug 17.

PMID:
30121370
28.

[15th annual conference of the DPKK : Molecular analysis in diagnosis and treatment].

Taubert H, Becker C, Borkowetz A, Seitz G, Kristiansen G, Wach S, Wullich B.

Urologe A. 2018 Aug;57(8):966-968. doi: 10.1007/s00120-018-0710-7. German. No abstract available.

PMID:
29934648
29.

Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT: A Pilot Study in Patients With Metastatic Prostate Cancer.

Schmidkonz C, Cordes M, Beck M, Goetz TI, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.

Clin Nucl Med. 2018 Aug;43(8):e250-e258. doi: 10.1097/RLU.0000000000002162.

PMID:
29916921
30.

Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.

Zinnall U, Weyerer V, Compérat E, Camparo P, Gaisa NT, Knuechel-Clarke R, Perren A, Lugli A, Toma M, Baretton G, Kristiansen G, Wirtz RM, Cheng L, Wullich B, Stoehr R, Hartmann A, Bertz S.

Hum Pathol. 2018 Oct;80:55-64. doi: 10.1016/j.humpath.2018.05.022. Epub 2018 Jun 6.

31.

68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer.

Schmidkonz C, Cordes M, Schmidt D, Bäuerle T, Goetz TI, Beck M, Prante O, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.

Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1862-1872. doi: 10.1007/s00259-018-4042-z. Epub 2018 May 3.

PMID:
29725716
32.

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. eCollection 2018 Mar 13.

33.

[Geriatric urology].

Kahlmeyer A, Wullich B, Wiedemann A.

Urologe A. 2018 Apr;57(4):387-388. doi: 10.1007/s00120-018-0621-7. German. No abstract available.

PMID:
29536117
34.

Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients.

Lieb V, Weigelt K, Scheinost L, Fischer K, Greither T, Marcou M, Theil G, Klocker H, Holzhausen HJ, Lai X, Vera J, Ekici AB, Horninger W, Fornara P, Wullich B, Taubert H, Wach S.

Oncotarget. 2017 Dec 30;9(12):10402-10416. doi: 10.18632/oncotarget.23781. eCollection 2018 Feb 13.

35.

Diagnostic potential of major and trace elements in the serum of bladder cancer patients.

Wach S, Weigelt K, Michalke B, Lieb V, Stoehr R, Keck B, Hartmann A, Wullich B, Taubert H, Chaudhri A.

J Trace Elem Med Biol. 2018 Mar;46:150-155. doi: 10.1016/j.jtemb.2017.12.010. Epub 2017 Dec 28.

PMID:
29413105
36.

SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer.

Schmidkonz C, Cordes M, Beck M, Goetz TI, Schmidt D, Prante O, Bäuerle T, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.

Clin Nucl Med. 2018 Apr;43(4):225-231. doi: 10.1097/RLU.0000000000001991.

PMID:
29401151
37.

Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma.

Bellut J, Bertz S, Nolte E, Stöhr C, Polifka I, Lieb V, Herrmann E, Jung R, Hartmann A, Wullich B, Taubert H, Wach S.

Sci Rep. 2017 Nov 27;7(1):16424. doi: 10.1038/s41598-017-16144-4.

38.

99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.

Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Goetz TI, Sanders JC, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.

Prostate. 2018 Jan;78(1):54-63. doi: 10.1002/pros.23444. Epub 2017 Nov 6.

PMID:
29105797
39.

[Report of the 24th annual conference of the Working Group Kidney Transplantation of the German Society of Urology in Erlangen].

Apel H, Putz J, Fornara P, Friedersdorff F, Dreikorn K, Stöckle M, Wullich B.

Urologe A. 2017 Sep;56(9):1182-1184. doi: 10.1007/s00120-017-0452-y. German. No abstract available.

PMID:
28681234
40.

Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.

Sikic D, Keck B, Wach S, Taubert H, Wullich B, Goebell PJ, Kahlmeyer A, Olbert P, Isfort P, Nimphius W, Hartmann A, Giedl J; Bridge Consortium.

PLoS One. 2017 Jun 20;12(6):e0179602. doi: 10.1371/journal.pone.0179602. eCollection 2017.

41.

Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort.

Vetterlein MW, Meyer CP, Leyh-Bannurah SR, Mayr R, Gierth M, Fritsche HM, Burger M, Keck B, Wullich B, Martini T, Bolenz C, Pycha A, Hanske J, Roghmann F, Noldus J, Bastian PJ, Gilfrich C, May M, Rink M, Chun FK, Dahlem R, Fisch M, Aziz A; PROMETRICS 2011 study group.

Clin Genitourin Cancer. 2017 Oct;15(5):e809-e817. doi: 10.1016/j.clgc.2017.04.021. Epub 2017 Apr 26.

PMID:
28550955
42.

[Diagnosis and Therapeutic Management in Kidney, Ureter and Bladder Trauma].

Hirsch K, Heinz M, Wullich B.

Aktuelle Urol. 2017 Feb;48(1):64-71. doi: 10.1055/s-0042-119131. Epub 2017 Apr 12. Review. German.

PMID:
28403495
43.

High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.

Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stöhr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W.

Transl Oncol. 2017 Jun;10(3):340-345. doi: 10.1016/j.tranon.2017.01.013. Epub 2017 Mar 22.

44.

Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls.

Goebel S, Kehlen A, Bluemke K, Altermann W, Schlaf G, Fischer K, Fornara P, Wullich B, Wach S, Taubert H.

Cancer Immunol Immunother. 2017 May;66(5):565-571. doi: 10.1007/s00262-017-1957-3. Epub 2017 Feb 9.

PMID:
28184970
45.

Analysis of Argonaute Complex Bound mRNAs in DU145 Prostate Carcinoma Cells Reveals New miRNA Target Genes.

Szczyrba J, Jung V, Beitzinger M, Nolte E, Wach S, Hart M, Sapich S, Wiesehöfer M, Taubert H, Wennemuth G, Eichner N, Stempfl T, Wullich B, Meister G, Grässer FA.

Prostate Cancer. 2017;2017:4893921. doi: 10.1155/2017/4893921. Epub 2017 Jan 5.

46.

A new semisynthetic cardenolide analog 3β-[2-(1-amantadine)- 1-on-ethylamine]-digitoxigenin (AMANTADIG) affects G2/M cell cycle arrest and miRNA expression profiles and enhances proapoptotic survivin-2B expression in renal cell carcinoma cell lines.

Nolte E, Wach S, Silva IT, Lukat S, Ekici AB, Munkert J, Müller-Uri F, Kreis W, Oliveira Simões CM, Vera J, Wullich B, Taubert H, Lai X.

Oncotarget. 2017 Feb 14;8(7):11676-11691. doi: 10.18632/oncotarget.14644.

47.

ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.

Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium.

Urol Int. 2017;98(3):282-289. doi: 10.1159/000453670. Epub 2016 Dec 17.

PMID:
27992871
48.

Rhabdoid and Undifferentiated Phenotype in Renal Cell Carcinoma: Analysis of 32 Cases Indicating a Distinctive Common Pathway of Dedifferentiation Frequently Associated With SWI/SNF Complex Deficiency.

Agaimy A, Cheng L, Egevad L, Feyerabend B, Hes O, Keck B, Pizzolitto S, Sioletic S, Wullich B, Hartmann A.

Am J Surg Pathol. 2017 Feb;41(2):253-262. doi: 10.1097/PAS.0000000000000787.

PMID:
27984237
49.

[Prerequisites, skills and productivity of young academic urologists in Germany].

Borgmann H, Bründl J, Huber J, Ruf C, Schagdarsurgengin U, Wullich B, Salem J.

Urologe A. 2017 Dec;56(12):1603-1610. doi: 10.1007/s00120-016-0287-y. German.

PMID:
27924352
50.

Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database.

May M, Protzel C, Vetterlein MW, Gierth M, Noldus J, Karl A, Grimm T, Wullich B, Grimm MO, Nuhn P, Bastian PJ, Roigas J, Hadaschik B, Gilfrich C, Burger M, Fisch M, Brookman-May S, Aziz A, Hakenberg OW; PROMETRICS 2011 Research Group.

Int Urol Nephrol. 2017 Feb;49(2):247-254. doi: 10.1007/s11255-016-1469-7. Epub 2016 Nov 28.

PMID:
27896578

Supplemental Content

Loading ...
Support Center